| Species |
Human |
| Protein Construction |
NKp30/NCR3/CD337 (Leu19-Thr138)_x000D_
Accession # AAH52582 |
hFc |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized NKp30/NCR3/CD337 hFc Chimera, Human at 1μg/ml (100μl/Well) on the plate can bind Biotinylated AntiNKp30 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
39.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 53-60 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
NKp30, along with NKp44 and NKp46, constitute a group of receptors termed 'Natural Cytotoxicity Receptors'. These receptors play a major role in triggering NK-mediated killing of most tumor cells lines.NKp30 stimulates NK cells cytotoxicity toward neighboring cells producing these ligands. It controls, for instance, NK cells cytotoxicity against tumor cells. Engagement of NCR3 by BAG6 also promotes myeloid dendritic cells (DC) maturation, both through killing DCs that did not acquire a mature phenotype, and inducing the release by NK cells of TNFA and IFNG which promote DC maturation. |
| Synonyms |
CD337; LY117; NCR3; NKp30; 1C7; MALS |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
